Literature DB >> 19632004

[Tree decision analysis of the therapeutic alternatives for Panic Disorders in Primary Care].

Fernando Navarro-Mateu1, Ascensión Garriga-Puerto, Juan Antonio Sánchez-Sánchez.   

Abstract

AIMS: To analyse the different therapeutic alternatives for Panic Disorders to make it easier to make collaborative treatment decisions between patients and doctors in a Primary Care setting.
DESIGN: Quantitative analysis by a decision tree. DATA SOURCES: Time period reviewed; 1990-2008 in Med-line, Embase, Cochrane-plus Library and Tripdatabase. Terms used "panic disorder", "psychotherapy" and "drug therapy".
METHODS: I) A decision tree was prepared with only one therapeutic option in each arm; II) The same procedure with two sequential therapeutic options; III) Sensitivity analysis to test the robustness of the model. STUDY SELECTION: Evidence summary, systematic reviews, meta-analysis and clinical guidelines.
RESULTS: Cognitive-Behavioural Therapy (CBT) obtains the highest usefulness (UME=0.58), followed by the Selective serotonin reuptake inhibitors (SSRI) (UME=0.53) and by the tricyclic antidepressants (UME=0.44). CBT followed by SSRI is the therapeutic sequence with the highest usefulness (0.62). The sensitivity analysis suggests the model is not robust enough.
CONCLUSIONS: The CBT in monotherapy or followed by SSRI in a sequential strategy would be the options with the highest usefulness. The results are not robust enough because they can clearly vary with changes in the most important variables in a reasonable range.

Entities:  

Mesh:

Year:  2009        PMID: 19632004      PMCID: PMC7022091          DOI: 10.1016/j.aprim.2009.05.003

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  14 in total

1.  Shared decision making in hypertension: the impact of patient preferences on treatment choice.

Authors:  A A Montgomery; J Harding; T Fahey
Journal:  Fam Pract       Date:  2001-06       Impact factor: 2.267

2.  Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder.

Authors:  M R Mavissakalian; J K Schmier; J A Flynn; D A Revicki
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

3.  A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia.

Authors:  Kristin Mitte
Journal:  J Affect Disord       Date:  2005-09       Impact factor: 4.839

Review 4.  Decision analysis.

Authors:  S G Pauker; J P Kassirer
Journal:  N Engl J Med       Date:  1987-01-29       Impact factor: 91.245

5.  Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.

Authors:  A Bakker; R van Dyck; P Spinhoven; A J van Balkom
Journal:  J Clin Psychiatry       Date:  1999-12       Impact factor: 4.384

6.  Individualizing treatment decisions. The likelihood of being helped or harmed.

Authors:  Sharon E Straus
Journal:  Eval Health Prof       Date:  2002-06       Impact factor: 2.651

Review 7.  Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review.

Authors:  Toshi A Furukawa; Norio Watanabe; Rachel Churchill
Journal:  Br J Psychiatry       Date:  2006-04       Impact factor: 9.319

8.  Brief intervention for anxiety in primary care patients.

Authors:  Peter Roy-Byrne; Jason P Veitengruber; Alexander Bystritsky; Mark J Edlund; Greer Sullivan; Michelle G Craske; Stacy Shaw Welch; Raphael Rose; Murray B Stein
Journal:  J Am Board Fam Med       Date:  2009 Mar-Apr       Impact factor: 2.657

Review 9.  Combined psychotherapy plus benzodiazepines for panic disorder.

Authors:  Norio Watanabe; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

10.  Tips for teachers of evidence-based medicine: making sense of decision analysis using a decision tree.

Authors:  Anna Lee; Gavin M Joynt; Anthony M H Ho; Sheri Keitz; Thomas McGinn; Peter C Wyer
Journal:  J Gen Intern Med       Date:  2009-02-27       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.